Symbicort (budesonide/formoterol) Turbuhaler + Conventional treatment
Phase 3Terminated 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Asthma, Bronchial
Conditions
Asthma, Bronchial
Trial Timeline
Sep 1, 2006 โ Oct 1, 2008
NCT ID
NCT00385593About Symbicort (budesonide/formoterol) Turbuhaler + Conventional treatment
Symbicort (budesonide/formoterol) Turbuhaler + Conventional treatment is a phase 3 stage product being developed by AstraZeneca for Asthma, Bronchial. The current trial status is terminated. This product is registered under clinical trial identifier NCT00385593. Target conditions include Asthma, Bronchial.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00385593 | Phase 3 | Terminated |
Competing Products
20 competing products in Asthma, Bronchial